Introduction: Gastrointestinal (GI) symptoms are common among patients with Parkinson's disease (PD), due to both the disease itself and anti-PD drugs. We hypothesized that transdermal drug administration may result in fewer GI problems. This prospective observational study (ClinicalTrials.gov: NCT01159691) investigated effect of switching to rotigotine transdermal patch from oral anti-PD medications in patients with PD and existing GI symptoms.
Methods: Patients were enrolled if their physician was planning to switch them to rotigotine because of GI symptoms experienced while receiving oral anti-PD medications. Effectiveness assessments included a visual analog scale (VAS) measuring intensity of GI symptoms from 0 (no disorder) to 100 mm (extremely severe disorder), a questionnaire on the frequency and intensity of six individual GI complaints (heartburn, bloating, nausea, vomiting, abdominal pain, diarrhea), each rated 0-12 for a sum score of 0-72, and patient satisfaction regarding GI symptoms over approximately 6 weeks after switching.
Results: Of 75 patients who received rotigotine, 58 had follow-up data available for final analysis. Intensity of GI complaints improved numerically on both the VAS (47.5 ± 24.4 mm [n = 65] at baseline, 19.7 ± 23.3 mm [n = 58] after around 6 weeks) and the sum score of GI complaints (11.2 ± 9.0 at baseline, 2.1 ± 4.4 [n = 58] after around 6 weeks). Fifty of 58 patients were "satisfied" or "very satisfied" regarding GI symptoms over around 6 weeks following switch to the patch.
Conclusion: This study suggests that a switch from oral anti-PD medications to rotigotine transdermal patch may improve existing GI symptoms among patients with PD. Additional controlled studies are needed to confirm this finding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.parkreldis.2014.11.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study aimed to compare the skin adhesion of a new rotigotine transdermal patch (ROT-TDS) to an existing product for patients with Parkinson's disease (PD).
- Research included pharmacokinetic testing on healthy adults and a trial on PD patients to assess adhesion and safety.
- Results showed that ROT-TDS had similar effectiveness and safety as the reference patch but also demonstrated better skin adhesion, with a higher percentage of patches staying adhered through the dosing period.
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.
J Clin Sleep Med
January 2025
Department of Neurology, Vanderbilt University, Nashville, Tennessee.
Introduction: This guideline establishes clinical practice recommendations for treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) in adults and pediatric patients.
Methods: The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths based on a systematic review of the literature and an assessment of the evidence using the grading of recommendations assessment, development, and evaluation methodology. The task force provided a summary of the relevant literature and the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations.
Chronic endothelial dopamine receptor stimulation improves endothelial function and hemodynamics in autosomal dominant polycystic kidney disease.
Kidney Int
December 2024
University Rouen Normandie, Institut national de la santé et de la recherche médicale (INSERM) U1096, Endothélium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France; Centre d'Investigation CLinique-Centre de Ressources Biologiques (CIC-CRB) 1404, Rouen, France. Electronic address:
Article Synopsis
- The study explores how altered endothelial flow sensitivity related to polycystin deficiency contributes to hypertension in autosomal dominant polycystic kidney disease (ADPKD) patients.
- Nineteen ADPKD patients were treated with the dopamine receptor agonist rotigotine, showing that a higher dose significantly improved nitric oxide release and endothelial function without major changes in overall blood pressure.
- The findings suggest that targeting endothelial dopamine receptors could be a promising new treatment strategy to mitigate cardiovascular issues linked with ADPKD.
Allergic contact dermatitis to sodium metabisulphite in a rotigotine transdermal therapeutic system.
Contact Dermatitis
December 2024
Serviço de Dermatologia, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal.
The Smart Drug Delivery of Rotigotine Using Transdermal Patch for the Successful Management of Parkinson's Disease.
Cent Nerv Syst Agents Med Chem
June 2024
Department of Pharmaceutics, S. A. Raja Pharmacy College, Vadakangulam, Tirunelveli- 627116, Tamil Nadu, India.
Background: A Non-Ergot Dopamine Agonist (NEDA) rotigotine has been designed as a new transdermal drug delivery system.
Aim: To maintain optimum homogeneity in drug content, the rotigotine transdermal patch was developed utilizing a solvent casting technique.
Methods: The characteristics of a transdermal patch, including patch weight, folding endurance, patch thickness, surface morphology, tensile strength, swelling rate, surface pH, in vitro release studies, water retention rate, uniformity of drug content, and ex-vivo permeation studies, were determined.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!